BIOMERICA INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
BIOMERICA INC (BMRA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $11.01 per share for the 12-month period ending 2026-05-31, per its 10-K filed 2026-08-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-31
- BIOMERICA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2026 was $11.01, a 18.26% decline from fiscal 2025.
- BIOMERICA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $13.47, a 63.55% decline from fiscal 2024.
- BIOMERICA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $36.95, a 564.57% increase from fiscal 2023.
- BIOMERICA INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $5.56, a 26.08% increase from fiscal 2022.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|
| 2026-05-31 | $11.01 10-K · filed 2026-08-31 | |||
| 2025-05-31 | $13.47 10-K · filed 2026-08-31 | |||
| 2024-05-31 | $36.95 10-K · filed 2025-08-29 | $4.64 10-K · filed 2024-08-28 | ||
| 2023-05-31 | $5.56 10-K · filed 2024-08-28 | |||
| 2023-02-28 | $4.76 10-Q · filed 2023-04-14 | |||
| 2022-11-30 | $5.07 10-Q · filed 2023-01-13 | |||
| 2022-05-31 | $4.41 10-K · filed 2023-08-25 | |||
| 2022-02-28 | $3.49 10-Q · filed 2022-04-14 | |||
| 2019-02-28 | $2.12 10-Q · filed 2019-04-15 | |||
| 2018-11-30 | $2.56 10-Q · filed 2019-01-14 | |||
| 2018-02-28 | $1.44 10-Q · filed 2018-04-16 | |||
| 2017-11-30 | $0.92 10-Q · filed 2018-01-17 | |||
| 2017-02-28 | $0.97 10-Q · filed 2017-04-14 | |||
| 2016-11-30 | $0.96 10-Q · filed 2017-01-17 | |||
| 2016-02-29 | $0.70 10-Q · filed 2016-04-14 | |||
| 2015-11-30 | $0.70 10-Q · filed 2016-01-14 | |||
| 2015-02-28 | $0.73 10-Q · filed 2015-04-14 | |||
| 2014-11-30 | $0.72 10-Q · filed 2015-01-14 | |||
| 2014-02-27 | $0.43 10-Q · filed 2014-04-14 | |||
| 2013-11-30 | $0.43 10-Q · filed 2014-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |